Meeder Asset Management Inc Supernus Pharmaceuticals, Inc. Transaction History

Meeder Asset Management Inc

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$25.99 - $33.85 $46,106 - $60,049	1,774 New	1,774 $47,000
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $28 - $35	1 Added 6.25%	17 $1,000
Q2 2022 Aug 08, 2022	SELL	$25.33 - $34.25 $5,800 - $7,843	-229 Reduced 93.47%	16 $0
Q1 2022 May 10, 2022	BUY	$28.51 - $32.9 $6,984 - $8,060	245 New	245 $8,000
Q4 2021 Feb 11, 2022	SELL	$26.37 - $34.22 $7,700 - $9,992	-292 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$23.54 - $31.39 $776 - $1,035	33 Added 12.74%	292 $8,000
Q2 2021 Aug 09, 2021	SELL	$26.72 - $33.19 $44,355 - $55,095	-1,660 Reduced 86.5%	259 $8,000
Q1 2021 Apr 28, 2021	BUY	$24.15 - $31.45 $46,343 - $60,352	1,919 New	1,919 $50,000
Q4 2020 Feb 09, 2021	SELL	$17.7 - $25.81 $87,544 - $127,656	-4,946 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$20.2 - $25.05 $99,909 - $123,897	4,946 New	4,946 $102,000
Q2 2019 Aug 05, 2019	SELL	$29.96 - $38.87 $24,537 - $31,834	-819 Closed	0 $0
Q1 2019 Apr 16, 2019	SELL	$32.77 - $41.99 $1,998 - $2,561	-61 Reduced 6.93%	819 $28,000
Q4 2018 Jan 17, 2019	BUY	$30.84 - $49.51 $22,698 - $36,439	736 Added 511.11%	880 $30,000
Q3 2018 Nov 02, 2018	SELL	$42.7 - $56.55 $4,099 - $5,428	-96 Reduced 40.0%	144 $0
Q2 2018 Jul 24, 2018	SELL	$44.1 - $59.85 $41,983 - $56,977	-952 Reduced 79.87%	240 $0
Q1 2018 May 03, 2018	SELL	$37.15 - $46.9 $49,372 - $62,330	-1,329 Reduced 52.72%	1,192 $55,000
Q4 2017 Feb 02, 2018	BUY	$36.4 - $42.6 $9,063 - $10,607	249 Added 10.96%	2,521 $100,000
Q3 2017 Oct 20, 2017	BUY	$36.75 - $49.65 $83,496 - $112,804	2,272	2,272 $91,000

286

60.7M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.14B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.